The Effect of Vitamin D and Its Analogs in Ovarian Cancer.
ovarian cancer
vitamin D
vitamin D analogs
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
18 Sep 2022
18 Sep 2022
Historique:
received:
29
07
2022
revised:
13
09
2022
accepted:
14
09
2022
entrez:
23
9
2022
pubmed:
24
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
Ovarian cancer is one of the deadliest cancers in women, due to its heterogeneity and usually late diagnosis. The current first-line therapies of debulking surgery and intensive chemotherapy cause debilitating side effects. Therefore, there is an unmet medical need to find new and effective therapies with fewer side effects, or adjuvant therapies, which could reduce the necessary doses of chemotherapeutics. Vitamin D is one of the main regulators of serum calcium and phosphorus homeostasis, but it has also anticancer effects. It induces differentiation and apoptosis, reduces proliferation and metastatic potential of cancer cells. However, doses that would be effective against cancer cause hypercalcemia. For this reason, synthetic and less calcemic analogs have been developed and tested in terms of their anticancer effect. The anticancer role of vitamin D is best understood in colorectal, breast, and prostate cancer and much less research has been done in ovarian cancer. In this review, we thus summarize the studies on the role of vitamin D and its analogs in vitro and in vivo in ovarian cancer models.
Identifiants
pubmed: 36145244
pii: nu14183867
doi: 10.3390/nu14183867
pmc: PMC9501475
pii:
doi:
Substances chimiques
Vitamins
0
Vitamin D
1406-16-2
Phosphorus
27YLU75U4W
Calcium
SY7Q814VUP
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Austrian Science Fund FWF
ID : P 29948
Pays : Austria
Organisme : FWF Austrian Science Fund and Herzfelder Family Fund
ID : P 32840-B
Organisme : FWF Austrian Science Fund
ID : P 29948-B28
Références
Sci Rep. 2021 Apr 5;11(1):7484
pubmed: 33820921
Gynecol Oncol. 2016 Oct;143(1):159-167
pubmed: 27106018
PLoS One. 2013;8(2):e56616
pubmed: 23424670
Nutr Cancer. 2022;74(7):2632-2643
pubmed: 34894920
Int J Gynaecol Obstet. 2012 Oct;119 Suppl 2:S118-29
pubmed: 22999503
Nutrients. 2022 Aug 18;14(16):
pubmed: 36014904
Int J Epidemiol. 2016 Oct;45(5):1619-1630
pubmed: 27594614
Nat Rev Cancer. 2014 May;14(5):342-57
pubmed: 24705652
Int J Epidemiol. 1994 Dec;23(6):1133-6
pubmed: 7721513
Nutr Cancer. 2022;74(4):1163-1170
pubmed: 34278890
Clin Cancer Res. 2005 Jan 1;11(1):323-8
pubmed: 15671562
Int J Mol Sci. 2021 Dec 24;23(1):
pubmed: 35008598
Front Oncol. 2021 Aug 05;11:691500
pubmed: 34422647
Recent Results Cancer Res. 2003;164:239-46
pubmed: 12899526
Curr Mol Med. 2012 Jun;12(5):634-51
pubmed: 22515981
Apoptosis. 2021 Apr;26(3-4):184-194
pubmed: 33515314
Endocr Relat Cancer. 2022 Jan 24;29(2):R33-R55
pubmed: 34935629
Exp Physiol. 1995 May;80(3):449-56
pubmed: 7640009
Eur J Clin Nutr. 2020 Nov;74(11):1498-1513
pubmed: 31959942
J Steroid Biochem Mol Biol. 2011 Aug;126(1-2):46-54
pubmed: 21550403
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
pubmed: 21646368
J Biol Chem. 2004 Dec 17;279(51):53213-21
pubmed: 15485861
Steroids. 2013 Oct;78(10):1003-14
pubmed: 23811018
BMJ. 2017 Oct 31;359:j4761
pubmed: 29089348
Nat Commun. 2017 Oct 17;8(1):990
pubmed: 29042553
J Lab Physicians. 2018 Jan-Mar;10(1):1-5
pubmed: 29403195
J Biol Chem. 2012 Nov 30;287(49):41297-309
pubmed: 23055531
Onco Targets Ther. 2016 Apr 19;9:2365-75
pubmed: 27143932
Nat Rev Dis Primers. 2016 Aug 25;2:16061
pubmed: 27558151
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Nutrients. 2013 Jan 10;5(1):111-48
pubmed: 23306192
Nutrients. 2020 Nov 19;12(11):
pubmed: 33227893
Med Hypotheses. 2020 Nov;144:110278
pubmed: 33254582
Cancer Prev Res (Phila). 2012 Nov;5(11):1330-6
pubmed: 23034146
Invest New Drugs. 2010 Oct;28(5):543-53
pubmed: 19582372
Semin Cancer Biol. 2022 Feb;79:217-230
pubmed: 32485310
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Matrix Biol. 2022 May;109:70-90
pubmed: 35339636
Endocr Rev. 2008 Oct;29(6):726-76
pubmed: 18694980
Mol Cell Endocrinol. 2011 Dec 5;347(1-2):61-9
pubmed: 21664249
Anticancer Res. 2021 Jun;41(6):2945-2952
pubmed: 34083285
Front Pharmacol. 2020 Aug 07;11:945
pubmed: 32848720
Ecancermedicalscience. 2020 Jul 23;14:1078
pubmed: 32863872
PLoS One. 2012;7(4):e34443
pubmed: 22509304
Oncotarget. 2018 Feb 16;9(18):14481-14491
pubmed: 29581858
J Ovarian Res. 2016 Apr 18;9:26
pubmed: 27091127
Int J Mol Sci. 2016 Aug 19;17(8):
pubmed: 27548154
Hum Mol Genet. 2018 Dec 15;27(24):4315-4322
pubmed: 30508204
J Steroid Biochem Mol Biol. 2019 Jan;185:1-6
pubmed: 29981368
Oncol Rep. 2019 Jun;41(6):3393-3403
pubmed: 31002352
Anticancer Res. 2020 Jun;40(6):3129-3138
pubmed: 32487607
J Clin Med. 2022 Jul 04;11(13):
pubmed: 35807169
Eur J Clin Nutr. 2021 Mar;75(3):417-429
pubmed: 32814859
Cancer Biol Med. 2017 Feb;14(1):9-32
pubmed: 28443200
Mol Cell Endocrinol. 2011 May 16;338(1-2):58-67
pubmed: 21458521
J Biol Chem. 2004 Jun 11;279(24):25260-7
pubmed: 15075339
Am J Clin Nutr. 2015 Jul;102(1):109-14
pubmed: 25971716
Mol Cancer Res. 2019 Feb;17(2):431-445
pubmed: 30401718
Nat Commun. 2021 Jan 11;12(1):246
pubmed: 33431812
Nutrients. 2022 Feb 19;14(4):
pubmed: 35215535
J Ovarian Res. 2022 Jun 23;15(1):75
pubmed: 35739532
Pathobiology. 2018;85(1-2):41-49
pubmed: 29020678